Johnson & Johnson (JNJ) Is At $145.33 Formed Wedge; Nektar Therapeutics Has 1.4 Sentiment

January 28, 2018 - By Jerrie Dane

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $12.45 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Johnson & Johnson (JNJ) formed wedge up with $149.69 target or 3.00% above today’s $145.33 share price. Johnson & Johnson (JNJ) has $390.43 billion valuation. The stock increased 0.64% or $0.93 during the last trading session, reaching $145.33. About 8.07 million shares traded or 37.06% up from the average. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since January 28, 2017 and is uptrending. It has underperformed by 4.16% the S&P500.

Camber Capital Management Llc holds 7.91% of its portfolio in Nektar Therapeutics for 5.20 million shares. First Light Asset Management Llc owns 503,193 shares or 3.82% of their US portfolio. Moreover, Bridger Management Llc has 3.27% invested in the company for 2.27 million shares. The Florida-based Harvey Capital Management Inc has invested 2.78% in the stock. Rhenman & Partners Asset Management Ab, a Sweden-based fund reported 866,194 shares.

Since January 1, 0001, it had 0 insider purchases, and 19 selling transactions for $25.56 million activity.

The stock increased 0.13% or $0.1 during the last trading session, reaching $79.03. About 2.50 million shares traded. Nektar Therapeutics (NKTR) has risen 41.52% since January 28, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on March, 7. They expect $-0.35 earnings per share, down 25.00% or $0.07 from last year’s $-0.28 per share. After $0.37 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -194.59% negative EPS growth.